1Q20 2Q20 3Q20 Cash position $15.8M $13.2M $37M Revenue $1.6M * $1.79M * $2.04M * ▲QoQ rev (7.3%) 7.2% 14.2% ▲ YoY rev (25.6%) ** 8.2% 9.3% Gross … [Read more...] about DRIO Q1-Q3, 2020 Financial Breakdown
Kintara Therapeutics (Nasdaq: KTRA) Remains Underappreciated Despite an Upbeat GBM Data Update at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting
Kintara Therapeutics (Nasdaq: KTRA) is a newly-formed, late-stage, oncology-focused pharmaceutical company resulting from the strategic acquisition of Adgero Biopharma by DelMar … [Read more...] about Kintara Therapeutics (Nasdaq: KTRA) Remains Underappreciated Despite an Upbeat GBM Data Update at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting
KTRA/DMPI SNO Historical Performance
Below is historical data of how KTRA (formally DMPI) performed after presenting at Society for Neural Oncology (SNO). KTRA is set to present data at (SNO) which is anticipated November 19th-22. The … [Read more...] about KTRA/DMPI SNO Historical Performance
La Jolla Pharmaceuticals (Nasdaq: LJPC) Investment Update
Initially, we accumulated LJPC between $2.30 and $2.50 in November of 2019. The buying opportunity came after LJPC announced the discontinuation of its research and development program and the … [Read more...] about La Jolla Pharmaceuticals (Nasdaq: LJPC) Investment Update
Gritstone Oncology (Nasdaq: GRTS) Investment Update
Here we reflect on the past quarter for GRTS. Subsequent to the Phase 1a/1b data update on 7/14/20 GRTS lost 50% of its market capitalization ($155M) in a single day with ~30% of outstanding … [Read more...] about Gritstone Oncology (Nasdaq: GRTS) Investment Update
Volatility Update 9-4-20
Chart Showing XBI breakdown 9-3-20 thru 9-4-20Broader Market ConditionsBetween yesterday and today the broader markets have been in a free-fall and the biotech sector was not immune despite missing … [Read more...] about Volatility Update 9-4-20
DarioHealth (Nasdaq: DRIO) Gains Traction on $28.6M Private Placement, New Contract Prospects, and M&A speculation
In my last article, following the 38th Annual JP Morgan Healthcare Conference, I presented my investment thesis for DarioHealth (Nasdaq: DRIO) as a growth play in the nascent Digital Therapeutics … [Read more...] about DarioHealth (Nasdaq: DRIO) Gains Traction on $28.6M Private Placement, New Contract Prospects, and M&A speculation
BioCryst Pharmaceuticals (Nasdaq: BCRX): Embarrassment of Riches
Founded in 1986 BioCryst Pharmaceuticals (BCRX) specializes in the development of novel, oral, small molecules that inhibit enzymes playing a key role in the biological pathway of rare diseases. … [Read more...] about BioCryst Pharmaceuticals (Nasdaq: BCRX): Embarrassment of Riches
La Jolla Pharmaceuticals (Nasdaq: LJPC): An Assessment of The Tetraphase Acquisition
For the past 8-months now our team has been long La Jolla Pharmaceuticals (Nasdaq: LJPC) calling for a substantial upside in the stock price. At times our thesis has played out such as with the … [Read more...] about La Jolla Pharmaceuticals (Nasdaq: LJPC): An Assessment of The Tetraphase Acquisition
DelMar Pharmaceuticals (NASDAQ: DMPI): A New Beginning
For the past 6-months our team at MS Money Moves has been following the story of DelMar Pharmaceuticals (NASDAQ: DMPI) in an effort to educate and inform the investment community. During this time, we … [Read more...] about DelMar Pharmaceuticals (NASDAQ: DMPI): A New Beginning
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish